摘要：

A series of 328 patients with advanced cancers of the stomach, pancreas, liver, and biliary tract were treated with intensive fluoropyrimidine therapy, including 5-FU, 5-FUDR, intra-arterial infusions of 5-FU, and 5-FU plus radiotherapy. Survival patterns were analyzed with particular emphasis on survival over 1 year after treatment was begun. Patients with stomach cancer had median survivals of 5–7 1/2 months; over-all survival of more than a year was seen in 22%. Radiation therapy plus 5-FU was associated with slightly longer survival, as was prior resection of the primary tumor. Patients with pancreatic cancer survived four months median, with 12.5% surviving longer than 1 year. Survial was most dependent on extent of disease at the onset of therapy. Hepatobiliary cancer continued to present a very bleak prognosis. However, excellent responses occurred in 3/31 patients with liver cell or bile duct carcinoma. Intra-arterial infusions for liver involvement in these patients appeared to contribute little benefit to over-all survival, although dramatic responses were observed in two patients with primary liver tumors. It would appear that fluoropyrimidine therapy may modestly increase over-all survival in advanced stomach cancer. Survival in pancreatic cancer does not seem to be favorably influenced by this therapy.

展开